Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
Neoadjuvant DPX-Survivac Aromatase Inhibition Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

- breast cancer. There will be sequential enrollment into 3 arms with an anticipated N=6 participants per arm for N=18 participants in total. All participants will receive letrozole 2.5 mg daily during the

erbb2
her2/neu-negative breast cancer
mammogram
letrozole
cyclophosphamide
  • 0 views
  • 04 Nov, 2021
  • 1 location
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE)

. Antihormone therapy, such as fulvestrant, letrozole, anastrozole, exemestane, or tamoxifen, may lessen the amount of estrogen made by the body. Giving radiation therapy, palbociclib, and hormone therapy may

  • 19 views
  • 09 Feb, 2022
  • 10 locations
Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

in combination with letrozole or fulvestrant. The research will be divided into two parts. In the first part, 15 to 24 subjects will be enrolled to determine the safety and tolerability of

erbb2
letrozole
metastasis
exemestane
tamoxifen
  • 66 views
  • 11 May, 2021
  • 1 location
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made

chemotherapy drug
letrozole
growth factor
paclitaxel
epidermal growth factor
  • 0 views
  • 22 Mar, 2022
  • 1 location
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (ROSALINE)

drug evaluation and biomarker research, the ROSALINE phase 2 study will evaluate the efficacy of Entrectinib (a potent inhibitor of ROS1 among other targets) in combination with letrozole (+ goserelin

  • 0 views
  • 26 May, 2022
  • 10 locations
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA)

or those who will initiate therapy with an AI (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of TOL2506, upon confirmation that estradiol (E2) levels of &lt

erbb2
her2/neu-negative breast cancer
mammogram
letrozole
exemestane
  • 1 views
  • 28 Jul, 2022
  • 24 locations
IVM With Low Cost Priming, Enhanced Oocyte Recovery, and Delayed Transfer (IVMprt)

A protocol was developed to improve pregnancy results after IVM compared to results from studies in the literature. Differences from most published protocols include the use of the Steiner-Tan needle to optimize oocyte environment during oocyte retrieval, use of oral medications and very low doses of FSH, and delayed embryo …

antral
follicle stimulating hormone
anti-mullerian hormone
transvaginal ultrasound
  • 323 views
  • 16 Feb, 2022
  • 1 location
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

In ER+ and HER2- breast cancer(BC) patients for whom BCS is not feasible, we investigate the rate of BCS can be increased while decreasing unnecessary chemotherapy thru selective neoadjuvant chemotherapy or neoadjuvant endocrine therapy using tools of nodal status, Ki-67, and multigene assay(Mammaprint)

erbb2
her2/neu-negative breast cancer
mammogram
letrozole
metastasis
  • 0 views
  • 25 Feb, 2022
  • 1 location
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4CDK4and CDK6 kinase activity. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 …

her2/neu-negative breast cancer
letrozole
growth factor
epidermal growth factor receptor
international normalized ratio
  • 0 views
  • 08 Aug, 2021
  • 1 location
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE)

AMBRE is a phase III study comparing two standard treatments as initial metastatic treatment in ER+/HER2- breast cancer (BC) patients with visceral metastasis and high burden disease: Chemotherapy and combination of endocrine therapy with abemaciclib.

serum bilirubin level
metastasis
adenocarcinoma
neutrophil count
fulvestrant
  • 0 views
  • 26 May, 2022
  • 2 locations